Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Saved in:
| Title: | Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. |
|---|---|
| Authors: | Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: a.p.kater@amsterdamumc.nl., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Kersting S; Department of Hematology, Haga Hospital, Den Haag, Netherlands., Enggaard L; Department of Hematology, Herlev Hospital, Copenhagen, Denmark., Veldhuis GJ; Department of Hematology, St Antonius Hospital, Sneek, Netherlands., Mous R; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands., Mellink CHM; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., van der Kevie-Kersemaekers AF; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Dobber JA; Laboratory of Special Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Poulsen CB; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark., Janssens A; Department of Hematology, UZ Leuven, Leuven, Belgium., Schjødt I; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dompeling EC; Department of Hematology, Isala Ziekenhuis, Zwolle, Netherlands., Ranti J; Department of Hematology, Turku University Central Hospital, Turku, Finland., Brieghel C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mattsson M; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden., Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Tran HTT; Department of Hematology, Akershus University Hospital, Lørenskog, Norway., Nasserinejad K; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2022 Jun; Vol. 23 (6), pp. 818-828. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
